ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer

Min Kyoung Kim; Kyung Ja Cho; Gui Young Kwon; Seung Il Park; Yong Hee Kim; Jong Hoon Kim; Ho Young Song; Ji Hoon Shin; Hwoon Yong Jung; Gin Hyug Lee; Kee Don Choi; Sung Bae Kim

doi:10.1016/j.ejca.2007.09.006

ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer

Min Kyoung Kim, Kyung Ja Cho, Gui Young Kwon, Seung Il Park, Yong Hee Kim, Jong Hoon Kim, Ho Young Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Sung Bae Kim

Research output: Contribution to journal › Article

69 Scopus citations

Abstract

We assessed whether expression of excision repair cross-complementation group 1 (ERCC1) and/or thymidylate synthase (TS) can predict clinical outcome after preoperative chemoradiotherapy (CRT) in patients with localised oesophageal cancer. Paraffin-embedded pretreatment tumour specimens collected by endoscopic biopsy from patients treated with preoperative CRT (5-fluorouracil/cisplatin or capecitabine/cisplatin plus radiation) were analysed by immunohistochemical assay. Between March 1993 and June 2005, 129 patients were treated with preoperative CRT followed by surgery; of these, 108 biopsy specimens were available for analysis, and 40% and 35% were positive for ERCC1 and TS, respectively. Patients with ERCC1-negative (p < 0.001) or TS-negative (p = 0.04) tumours were significantly more likely to achieve pathologic major response. In multivariate analysis, ERCC1 was the only independent variable predicting pathologic response (p < 0.001). Patients with ERCC1-negative tumours showed tendencies toward prolonged overall survival (p = 0.10) and event free survival (p = 0.08). Prospective studies are required to determine the benefit of preoperative CRT in ERCC1-negative tumours.

Original language	English (US)
Pages (from-to)	54-60
Number of pages	7
Journal	European Journal of Cancer
Volume	44
Issue number	1
DOIs	https://doi.org/10.1016/j.ejca.2007.09.006
State	Published - Jan 1 2008
Externally published	Yes

Keywords

Combined modality therapy
ERCC1
Oesophageal neoplasms

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ejca.2007.09.006

Fingerprint Dive into the research topics of 'ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer'. Together they form a unique fingerprint.

Cite this

Kim, M. K., Cho, K. J., Kwon, G. Y., Park, S. I., Kim, Y. H., Kim, J. H., Song, H. Y., Shin, J. H., Jung, H. Y., Lee, G. H., Choi, K. D., & Kim, S. B. (2008). ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. European Journal of Cancer, 44(1), 54-60. https://doi.org/10.1016/j.ejca.2007.09.006

ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. / Kim, Min Kyoung; Cho, Kyung Ja; Kwon, Gui Young; Park, Seung Il; Kim, Yong Hee; Kim, Jong Hoon; Song, Ho Young; Shin, Ji Hoon; Jung, Hwoon Yong; Lee, Gin Hyug; Choi, Kee Don; Kim, Sung Bae.

In: European Journal of Cancer, Vol. 44, No. 1, 01.01.2008, p. 54-60.

Research output: Contribution to journal › Article

@article{cbe3fb7bfa3448118d32f55b995ebfa2,

title = "ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer",

abstract = "We assessed whether expression of excision repair cross-complementation group 1 (ERCC1) and/or thymidylate synthase (TS) can predict clinical outcome after preoperative chemoradiotherapy (CRT) in patients with localised oesophageal cancer. Paraffin-embedded pretreatment tumour specimens collected by endoscopic biopsy from patients treated with preoperative CRT (5-fluorouracil/cisplatin or capecitabine/cisplatin plus radiation) were analysed by immunohistochemical assay. Between March 1993 and June 2005, 129 patients were treated with preoperative CRT followed by surgery; of these, 108 biopsy specimens were available for analysis, and 40% and 35% were positive for ERCC1 and TS, respectively. Patients with ERCC1-negative (p < 0.001) or TS-negative (p = 0.04) tumours were significantly more likely to achieve pathologic major response. In multivariate analysis, ERCC1 was the only independent variable predicting pathologic response (p < 0.001). Patients with ERCC1-negative tumours showed tendencies toward prolonged overall survival (p = 0.10) and event free survival (p = 0.08). Prospective studies are required to determine the benefit of preoperative CRT in ERCC1-negative tumours.",

keywords = "Combined modality therapy, ERCC1, Oesophageal neoplasms",

author = "Kim, {Min Kyoung} and Cho, {Kyung Ja} and Kwon, {Gui Young} and Park, {Seung Il} and Kim, {Yong Hee} and Kim, {Jong Hoon} and Song, {Ho Young} and Shin, {Ji Hoon} and Jung, {Hwoon Yong} and Lee, {Gin Hyug} and Choi, {Kee Don} and Kim, {Sung Bae}",

year = "2008",

month = jan,

day = "1",

doi = "10.1016/j.ejca.2007.09.006",

language = "English (US)",

volume = "44",

pages = "54--60",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer

AU - Kim, Min Kyoung

AU - Cho, Kyung Ja

AU - Kwon, Gui Young

AU - Park, Seung Il

AU - Kim, Yong Hee

AU - Kim, Jong Hoon

AU - Song, Ho Young

AU - Shin, Ji Hoon

AU - Jung, Hwoon Yong

AU - Lee, Gin Hyug

AU - Choi, Kee Don

AU - Kim, Sung Bae

PY - 2008/1/1

Y1 - 2008/1/1

N2 - We assessed whether expression of excision repair cross-complementation group 1 (ERCC1) and/or thymidylate synthase (TS) can predict clinical outcome after preoperative chemoradiotherapy (CRT) in patients with localised oesophageal cancer. Paraffin-embedded pretreatment tumour specimens collected by endoscopic biopsy from patients treated with preoperative CRT (5-fluorouracil/cisplatin or capecitabine/cisplatin plus radiation) were analysed by immunohistochemical assay. Between March 1993 and June 2005, 129 patients were treated with preoperative CRT followed by surgery; of these, 108 biopsy specimens were available for analysis, and 40% and 35% were positive for ERCC1 and TS, respectively. Patients with ERCC1-negative (p < 0.001) or TS-negative (p = 0.04) tumours were significantly more likely to achieve pathologic major response. In multivariate analysis, ERCC1 was the only independent variable predicting pathologic response (p < 0.001). Patients with ERCC1-negative tumours showed tendencies toward prolonged overall survival (p = 0.10) and event free survival (p = 0.08). Prospective studies are required to determine the benefit of preoperative CRT in ERCC1-negative tumours.

AB - We assessed whether expression of excision repair cross-complementation group 1 (ERCC1) and/or thymidylate synthase (TS) can predict clinical outcome after preoperative chemoradiotherapy (CRT) in patients with localised oesophageal cancer. Paraffin-embedded pretreatment tumour specimens collected by endoscopic biopsy from patients treated with preoperative CRT (5-fluorouracil/cisplatin or capecitabine/cisplatin plus radiation) were analysed by immunohistochemical assay. Between March 1993 and June 2005, 129 patients were treated with preoperative CRT followed by surgery; of these, 108 biopsy specimens were available for analysis, and 40% and 35% were positive for ERCC1 and TS, respectively. Patients with ERCC1-negative (p < 0.001) or TS-negative (p = 0.04) tumours were significantly more likely to achieve pathologic major response. In multivariate analysis, ERCC1 was the only independent variable predicting pathologic response (p < 0.001). Patients with ERCC1-negative tumours showed tendencies toward prolonged overall survival (p = 0.10) and event free survival (p = 0.08). Prospective studies are required to determine the benefit of preoperative CRT in ERCC1-negative tumours.

KW - Combined modality therapy

KW - ERCC1

KW - Oesophageal neoplasms

UR - http://www.scopus.com/inward/record.url?scp=37149046306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149046306&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2007.09.006

DO - 10.1016/j.ejca.2007.09.006

M3 - Article

C2 - 17976974

AN - SCOPUS:37149046306

VL - 44

SP - 54

EP - 60

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -